Moderna's Q3 Beat Draws Two Very Different Price Targets — and a Canadian First
Published on 11/11/2026 at 13:31 | Editorial boerse-global.de
Moderna closed out its third quarter with a return to profit and a sharply brighter revenue outlook, but Wall Street is still split on how much of that turnaround is already baked into the share price. Two analysts raised their targets on Monday, yet their recommendations landed on opposite sides of the fence.
The Numbers Behind the Re-Rating
Revenue for the third quarter of 2026 climbed 29% year over year to $1.31 billion, the company reported on Friday. Net income under GAAP came in at $0.2 billion, or $0.38 per diluted share — a figure one source pegs at $162 million on a net basis. Product sales accounted for $1.27 billion of the top line.
Alongside those results, Moderna lifted its full-year 2026 revenue growth guidance to 15%–25%, up from an earlier forecast of up to 10%. The combination of the quarterly beat and the raised bar was credited with sparking the rally that followed. The company also guided toward a year-end cash position of $8.1 billion to $8.3 billion and has scheduled an analyst day for November 12, 2026.
Two Houses, Two Verdicts
Piper Sandler moved its price target to $305 from $230 on Monday while reaffirming an Overweight rating, pointing to the $1.27 billion in product revenue and the upgraded growth outlook. Goldman Sachs raised its own target to $195 from $137 but kept a Neutral stance. Despite both hikes, the two firms remain far apart on what Moderna is worth.
Should investors sell immediately? Or is it worth buying Moderna?
The stock added 2.5% in the latest session, with no separate catalyst identified for that particular move.
A Pullback, Not a Verdict
Tuesday told a different story: shares fell 6.1% as investors booked profits following the post-earnings surge, with a softer broader market adding pressure on volatile biotech names. That retreat says more about trading rhythm than about the business itself — the operating story kept running while the ticker caught its breath.
Canada Breaks New Ground
The more durable development came on the pipeline front. Health Canada on November 5 approved both mFLUSIVA, a seasonal mRNA flu shot, and mCOFLU, a combined influenza and COVID-19 vaccine. According to the company, Canada is the first country to clear both products — giving Moderna approvals for a standalone flu vaccine and a combination shot, and a foothold for a broader product base if the cleared offerings gain commercial traction.
Ebola and Melanoma: The Research Ledger
Outside flu, Moderna said on November 4 that the WHO's technical advisory group had recommended its experimental mRNA-1469 vaccine against Bundibugyo Ebola for an efficacy study, based on Phase 1 clinical results. The recommendation moves the program to a point where its viability can be tested in a full efficacy trial.
Moderna at a turning point? This analysis reveals what investors need to know now.
Not every headline has been kind. Moderna and Merck published full Phase 3 results for their experimental melanoma cancer vaccine on October 22, and Moderna's shares fell following the release, according to a report from the Associated Press.
What Actually Matters
Strip away the daily noise and a cleaner yardstick emerges: a profitable quarter supplies the financial footing, Canada widens the product horizon, and the research pipeline opens further options. The open question is how reliably Moderna converts those gains into recurring business results — a measure that will be tested far better by coming quarters, and by the November 12 analyst day, than by the direction of any single trading session.
Ad
Moderna Stock: New Analysis - 11 November
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
